Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | EGLN1 | Q9GZT9 | 2/20 | 0.43 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | MLNR | O43193 | 1/20 | 0.36 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.36 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.35 |
| ▸ | LPAR5 | Q9H1C0 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP8 | P22894 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | MMP17 | Q9ULZ9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1092355 | 0.89 | GRM2 (0.43) | GRM2LMNAHTTNPSR1MMP2 | |
| SCHEMBL2025352 | 0.88 | GRM2 (0.42) | EGLN1GRM2MEN1KMT2A | |
| SCHEMBL1091412 | 0.85 | EGLN1 (0.44) | EGLN1GRM2MLNRMMP2MMP14 | |
| SCHEMBL2023569 | 0.85 | MAPK1 (0.42) | GRM2LMNA | |
| SCHEMBL2022393 | 0.84 | GRM2 (0.42) | DAOEGLN1GRM2MEN1KMT2A | |
| SCHEMBL1091681 | 0.83 | GRM2 (0.42) | DAOEGLN1GRM2 | |
| SCHEMBL2027520 | 0.82 | PARK7 (0.46) | GRM2MEN1KMT2A | |
| SCHEMBL1091219 | 0.82 | GRM2 (0.41) | DAOEGLN1GRM2MEN1KMT2A | |
| SCHEMBL2025050 | 0.82 | PARP1 (0.48) | MEN1KMT2A | |
| SCHEMBL1091895 | 0.82 | CHRM5 (0.42) | GRM2LTA4H |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807706-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2010-10-05 | — | — | US | claimed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | claimed |
| EP-1912939-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | claimed |
| WO-2007021308-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | claimed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| US-8153638-B2 | Metabotropic glutamate-receptor-potentiating isoindolones | ASTRAZENECA AB (SE) | 2012-04-10 | — | — | US | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| EP-2357169-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | AstraZeneca AB (SE) | 2011-08-17 | — | — | EP | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-7968570-B2 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2011-06-28 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | US | disclosed |
| EP-1912939-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | AstraZeneca AB (SE) | 2008-04-23 | — | — | EP | disclosed |
| WO-2007021308-A1 | METABOTROPIC GLUTAMATE-RECEPTOR-POTENTIATING ISOINDOLONES | ASTRAZENECA AB (SE) | 2007-02-22 | — | — | WO | disclosed |
| WO-2006020879-A1 | ISOINDOLONE COMPOUNDS AND THEIR USE AS METABOTROPIC GLUTAMATE RECEPTOR POTENTIATORS | ASTRAZENECA AB (SE) | 2006-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | DAO 2081/4885EGLN1 3920/4885GRM2 4/4885 |
| US-20080227794-A1 | Metabotropic Glutamate-Receptor-Potentiating Isoindolones | GRM1, GRIN1, GRM2 | DAO 1504/4885EGLN1 3626/4885GRM2 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.